Fate Therapeutics, Inc. (FATE) Cash Flow Statement
Fate Therapeutics, Inc. (FATE) generated -$101.9M of operating cash flow over the twelve months to 2026-06-30, spent $3.7M on capital expenditure and had free cash flow of -$105.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FATEFate Therapeutics, Inc.Follow FATE — free
—
Price chart with a free account
- Market cap
- 252.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2013 Dec 13 | FY2015 Dec 15 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -15.4 | -18.4 | -38.7 | -83.2 | -39.2 | -162.9 | -248.2 | -132.3 | -122.9 | -106.1 | -101.9 | |
| Capital expenditure | 0.2 | 1.5 | 2.3 | 7.4 | 4.9 | 50.7 | 35.6 | 6.2 | 0.7 | 6.0 | -3.7 | |
| Free cash flow | -15.6 | -19.9 | -41.0 | -90.6 | -44.2 | -213.6 | -283.8 | -138.4 | -123.6 | -112.0 | -105.6 | |
| Stock-based compensation | 1.6 | 2.4 | — | — | — | — | — | — | — | — | — |
USD millions · SEC XBRL
Fate Therapeutics, Inc. — questions
- What is Fate Therapeutics, Inc.'s operating cash flow?
- -$101.9M over the twelve months to 2026-06-30.
- How much does Fate Therapeutics, Inc. spend on capital expenditure?
- $3.7M over the twelve months to 2026-06-30.
- What is Fate Therapeutics, Inc.'s free cash flow?
- -$105.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Fate Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.